News By Tag Industry News News By Place Country(s) Industry News
|  Just Released: "Tarceva (Pancreatic Cancer) - Analysis and Forecasts to 2020"Recently published research from GlobalData, "Tarceva (Pancreatic Cancer) - Analysis and Forecasts to 2020", is now available at Fast Market Research
By: Fast Market Research, Inc. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Scope * Therapy area profile including patient population for the US, EU5 and Japan (seven major markets) * Analysis and review of Tarceva including sales data * Qualitative and quantitative assessment of market space * Analysis of the trends, drivers and restraints shaping and defining the markets * In-depth analysis of Tarceva including efficacy, safety, pricing, competition and other details which influence its sales potential * Detailed sales forecasts from 2005-2020 for Tarceva in the seven major markets Reasons to Get this Report * Understand and capitalize by identifying products that are most likely to ensure a robust return * Stay ahead of competition by understanding the changing competitive landscape * Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential * Make more informed business decisions from insightful and in-depth analysis of the drug's performance * Examine the historical sales performance of a drug in seven major markets * Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets Tarceva, Pancreatic cancer, erlotinib, Sales forecast, EGFR, tyrosine kinase inhibitor, phase III, phase 3, pipeline, GVAX, HyperAcute Pancreas, Irinotecan, Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Genentech, Roche, OSI Pharmaceuticals, Chugai Partial Table of Contents: 1 Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Pancreatic Cancer 2.2 Pancreatic Cancer Market 2.3 Epidemiology 2.4 Etiology 2.5 The Main Recognized Risk factors 2.5.1 Cigarette Smoking 2.5.2 Age 2.5.3 Gender 2.5.4 Family History 2.5.5 Other Factors 2.5.6 Pancreatic Cancer Prevention 2.6 GlobalData Report Guidance 3 Pancreatic Cancer: Market Characterization 3.1 Pancreatic Cancer Disease Market 3.2 Pancreatic Cancer Disease Market Forecasts and CAGR 3.3 Drivers for the Pancreatic Cancer Disease Market 3.3.1 High Incidence 3.3.2 Large Unmet Need 3.3.3 Active Pipeline 4 Tumor-Node-Metastases (TNM) Classification of Pancreatic Cancer 4.1 Treatment Options in Pancreatic Cancer 4.2 Classification of Patients with Pancreatic Cancer 5 Tarceva 5.1 Introduction 5.2 Mechanism of Action 5.3 Clinical Studies 5.4 Approval History of Tarceva 5.5 Factors Affecting Sales of Tarceva 5.5.1 Efficacious therapy in comparison with gemcitabine 5.5.2 Competition to intensify in future 5.5.3 Patent Expiry of Gemzar 5.6 Drug Evaluation 5.6.1 Drug Risk Benefit Score 5.6.2 Intensity of Competition 5.7 Sales Forecasts 5.7.1 Target Patient Pool of Tarceva 5.7.2 Dosing 5.7.3 Market Penetration 5.7.4 Annual Cost of Therapy 5.7.5 Sales Projections of Tarceva 6 Appendix 6.1 Market Definitions 6.2 Abbreviations 6.3 Research Methodology 6.3.1 Coverage 6.3.2 Secondary Research 6.3.3 Forecasting 6.3.4 Number of Patients Approved to take the Drug 6.3.5 Net Penetration of Drug 6.3.6 Net Annual Dosing 6.3.7 Annual Cost of Therapy 6.4 Drug Sales Estimates Model 6.5 Contact Us 6.6 Disclaimer 6.7 Sources List of Tables 1.1 List of Tables Table 1: Pancreatic cancer, Estimated Incidence and Mortality, 2008-2030 Table 2: Pancreatic Cancer, TNM Classification Table 3: Approval History of Tarceva Table 4: Drug Risk Benefit Score of Tarceva Table 5: Tarceva, Pancreatic cancer, Global, Annual Cost of Therapy, 2011 Table 6: Tarceva, Pancreatic Cancer, Global, Sales Estimates ($m), 2005-2020 Table 7: Tarceva, Pancreatic Cancer, The US, Sales Estimates ($m), 2005-2020 Table 8: Tarceva, Pancreatic Cancer, The UK, Sales Estimates ($m), 2007-2020 Table 9: Tarceva, Pancreatic Cancer, France, Sales Estimates ($m), 2007-2020 Table 10: Tarceva, Pancreatic Cancer, Germany, Sales Estimates ($m), 2007-2020 Table 11: Tarceva, Pancreatic Cancer, Italy, Sales Estimates ($m), 2007-2020 Table 12: Tarceva, Pancreatic Cancer, Spain, Sales Estimates ($m), 2007-2020 Table 13: Tarceva, Pancreatic Cancer, Japan, Sales Forecasts ($m), 2011-2020 List of Figures 1.2 List of Figures Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2008 Figure 2: Total number of cigarettes consumed, The US, 1976-2006 Figure 3: Average Incidence Rate per 100,000, Pancreatic Cancer, the US, Both Sexes, 1992-2007 Figure 4: Incidence Rate per 100000, Pancreatic Cancer, the US, Both Sexes, 2010-2030 Figure 5: Pancreatic Cancer, Global, Market Size Forecasts ($m), 2010-2020 Full Table of Contents is available at: -- http://www.fastmr.com/ About GlobalData GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number